Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
Arcus Biosciences presented promising results for its kidney cancer treatment on Tuesday, which competitors Merck have also been developing. Following this announcement, the shares of Arcus Biosciences experienced a significant increase, rebounding from a premarket decline. This sudden surge in share value was driven by the positive reception of the Merck-rivaling cancer treatment reveal.